Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab for Relapsed/Refractory Mycosis Fungoides/Sezary Syndrome
NCT02243579Phase 2
Key facts
- Status
- Completed
- Start
- Oct 2014
- Primary completion
- Jan 2018
- Countries
- 1
- Sponsor
- National Cancer Institute
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Drugs
- pembrolizumab
- Conditions
- mycosis fungoides (MF)Sézary syndrome (SS)
01
Overview
Phase 2, open-label, single-arm trial of pembrolizumab in mycosis fungoides (MF) and Sézary syndrome (SS), sponsored by National Cancer Institute. Primary endpoint: Objective Response Rate at 3.2 years. Started Oct 2014; status: completed.
02
Design
1 arm- Study design
- Non-randomizedOpen-label
Treatment (pembrolizumab)
Pembrolizumab IV every 3 weeks
03
Who it enrols
Patients with stage IB-IVB MF/SS who have relapsed or are refractory to at least one standard systemic therapy.
04
Endpoints
Primary
Objective Response Rate
Secondary
Duration of Response
Progression Free Survival
Overall Survival
Time to Onset of First Drug-related Toxicity
Incidence of Adverse Events
Beyond the preview
Go deeper on NCT02243579.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02243579.